Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA)
Health Care · Biotechnology · US
$13.89
+3.12% today · +52.5% 1Y
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $392.32M and employs 120 people.
Over the last twelve months the share price has gained 52.5%, trading between 7.05 and 17.15.
Tweenvest scores Enanta Pharmaceuticals, Inc. across four factors: quality 36/100, value 62/100, growth 0/100. Its strongest factor is value.
ENTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $392.32M
- Revenue (TTM)
- $65.26M
- P/E
- —
- EPS
- -2.34
- Dividend yield
- —
- Beta (5Y)
- 0.93
- 52-week high
- $17.15
- 52-week low
- $7.05
- Avg volume (3M)
- —
- Shares outstanding
- 29.13M
- Employees
- 120
- Next earnings
- —
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
- ISIN
- US29251M1062
- Founded
- 1995
- Listed since
- Mar 21, 2013
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.81 | -0.06% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.42 | +0.93% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.50 | +0.26% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.72 | +0.12% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $827.67 | -0.76% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.38 | -3.92% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.